Bistable

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bistable

Property Description
Active ingredient Bisoprolol fumarate
Form Tablets
Pharmacological class beta1-selective Beta-blocker
Common use Modulating cardiac activity
Origin Synthetic compound

Bistable: An Overview of the Drug Entity

Bistable is a synthetic, prescription-only medication that is primarily delivered as tablets for oral administration. The medicine contains the active substance bisoprolol fumarate, commonly known as Bisoprolol (INN). Pharmacological studies indicate Bisoprolol's stability and reliability as a foundational single-ingredient agent. The requirement for a prescription strictly defines its usage, emphasizing the necessity of direct medical supervision. Bistable, as a brand, is recognized for its focused positioning in the treatment of chronic cardiovascular conditions.


What Type of Beta-Blocker is Bistable?

Bistable is categorized within the pharmacological class of beta-adrenergic blocking agents, generally known as beta-blockers or adrenergic beta-antagonists. More specifically, it is a mathbfbetamathbf1-selective beta-adrenergic blocking agent, a characteristic also described as cardioselectivity. This means the agent acts predominantly on the mathbfbetamathbf1-adrenergic receptors found chiefly in the heart and the juxtaglomerular cells of the kidney, limiting its effect on beta2-receptors located elsewhere in the body. The beta1-selectivity of Bisoprolol is clinically recognized for offering a more targeted action profile compared to older, non-selective analogues.


Bistable's General Purpose and Action Principle

The general purpose of Bistable is to serve as an antihypertensive agent and an anti-arrhythmia drug by modulating cardiac activity. It achieves this through a high-level action principle involving Heart Rate Regulation, Force Reduction, and Adrenaline Shielding. By acting as a competitive antagonist at the beta1 receptors, Bisoprolol reduces the strain and workload on the heart muscle. This therapeutic goal aligns with the medicine's role in stabilizing heart function and maintaining balanced circulatory pressure, which is a typical use scenario for patients needing long-term cardiovascular support.

Regulatory References

  1. pharmacological class of beta-adrenergic blocking agents

What side effects are possible with Bistable?

Possible side effects and safety information

The official safety profile of Bistable (Bisoprolol fumarate) is characterized by adverse reactions categorized by frequency and the organ systems affected, as documented by governmental regulatory authorities (e.g., EMA, FDA). This information establishes the recognized risks without providing clinical advice.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on their documented occurrence rates:

  • Very Common (occurs in 10% or more of patients, particularly in chronic heart failure): Bradycardia (slow heart rate).
  • Common (occurs in 1% to 10% of patients): Dizziness, headache, fatigue, asthenia, hypotension, and gastrointestinal complaints (e.g., nausea, diarrhea, constipation). Symptoms like dizziness and fatigue often appear at the beginning of the therapy and are typically transient.
  • Uncommon (occurs in 0.1% to 1% of patients): AV-conduction disturbances, sleep disorders, depression, and bronchospasm (in susceptible patients).
  • Rare (occurs in 0.01% to 0.1% of patients): Syncope, hallucinations, hepatitis, and erectile dysfunction.

Serious Safety Considerations

Regulatory documents identify key safety constraints. Serious adverse reactions include the worsening of pre-existing heart failure and significant AV-conduction disturbances. The medicine is contraindicated in several severe conditions, including cardiogenic shock and marked sinus bradycardia.

Population-Specific Notes

The safety and efficacy of Bistable have not been established in the pediatric population, and its use is not recommended in children. Caution is required for patients with severe renal or hepatic impairment, as elimination may be slower. Treatment must not be stopped abruptly in patients with coronary artery disease due to the documented risk of severe cardiac events.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Bistable (bisoprolol fumarate) is officially documented to present primarily with signs of cardiovascular depression. These manifestations include severe bradycardia (slow heart rate) and marked hypotension (low blood pressure). Other documented clinical changes may involve respiratory distress, such as difficulty breathing, or central nervous system effects, including confusion, dizziness, fainting, and in severe cases, seizures or collapse.

Regulators emphasize that urgent action is mandatory. Immediate medical help must be sought for any suspected overdose. Emergency services must be contacted right away if the individual collapses, experiences a seizure, or has severe trouble breathing.

Management requires that therapy with Bistable be stopped and supportive and symptomatic treatment provided. The official labeling states that no specific antidote is documented. Supportive measures, such as the use of sympathomimetic agents or intravenous fluids, are administered under close hospital monitoring.

A specific note from regulatory information highlights that low blood sugar (hypoglycemia) is a commonly documented concern in children following this type of overdose.

Therapeutic Uses of Bistable

Bistable (bisoprolol fumarate) is commonly used for managing chronic cardiovascular conditions, supporting stability and easing symptomatic burden across several domains. The medication is frequently utilized to assist with high blood pressure, heart failure, and angina.

Controlling Chronic High Blood Pressure

This domain addresses symptoms related to systemic imbalance that create noticeable physiological strain. Bistable is generally used to reduce the sustained physiological strain on the heart and blood vessels. The goal is to provide cardiovascular support, which may assist in reducing the long-term risk associated with these conditions.

Stabilizing Chronic Heart Failure and Prognosis

Bistable is considered relevant to the care for individuals with chronic heart failure with reduced ejection fraction who are clinically stable. It supports long-term patient support by easing the overall symptom load.

“This use contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.”

Quick Fact: Relief for Cardiac Strain

This medication is relevant for reducing the likelihood of heart-failure-related hospitalizations in stable patients, and is applied in conditions characterized by periods of heightened symptoms, such as recurrent chest pain (chronic stable angina) and rapid heart rate fluctuations.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bistable — official regulatory information

The eligibility for Bistable (bisoprolol fumarate) is strictly defined by regulatory authorities based on a patient's age and pre-existing medical conditions.


Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults with chronic stable heart conditions such as Hypertension, Chronic Stable Angina, and Stable Chronic Heart Failure.
Populations for whom use is contraindicated Cardiogenic Shock, Acute Heart Failure or decompensation, Second or Third Degree AV Block (without a pacemaker), Severe Bronchial Asthma, Severe COPD, or Untreated Phaeochromocytoma.
Age-related eligibility rules Pediatric Population (Children and Adolescents): Safety and efficacy have not been established; use cannot be recommended. Older Adults: No dosage adjustment is generally required based on age alone.
Pregnancy and lactation eligibility status Pregnancy: Use is recommended only if clearly needed. Lactation: Use is not recommended due to a lack of data on excretion into human milk.
Eligibility-related restrictions Use with caution in patients with Diabetes Mellitus (can mask hypoglycemia symptoms) or Severe Renal/Hepatic Impairment (therapeutic experience is limited or lacking in heart failure patients).

Connection to the overall eligibility profile

Official regulatory documents define eligibility primarily by a list of absolute contraindications that prohibit use in specific severe cardiac or respiratory conditions. Eligibility is limited by age, as the medicine is not recommended for the pediatric population where data is not established. Conditional use or caution is required for patient groups with organ impairment or specific comorbid diseases, such as severe hepatic impairment or diabetes mellitus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bistable (bisoprolol fumarate) interacts with several other medicinal products, with documented interactions categorized by official regulatory bodies based on mechanism and severity. These interactions are defined as:

  • Contraindicated Combinations: Co-administration is formally restricted with other beta-blocking agents due to the potential for an excessive reduction of sympathetic activity. Combinations with Floctafenine and Sultopride are also explicitly prohibited.
  • Combinations Not Recommended: Concomitant use with Calcium Antagonists of the Verapamil or Diltiazem type is generally not recommended, as they can negatively affect myocardial contractility and atrioventricular conduction.
  • Pharmacodynamic Interactions: Additive effects are documented with Digitalis Glycosides (Digoxin) and Class I Antiarrhythmic Drugs, increasing the risk of bradycardia and potentiating effects on atrioventricular conduction time. Close monitoring is required with Catecholamine-Depleting Drugs (e.g., Reserpine) for excessive sympathetic reduction.
  • Pharmacokinetic Alterations: The antibiotic Rifampin is officially stated to increase the metabolic clearance of bisoprolol fumarate, which shortens its elimination half-life. The absorption of bisoprolol is not affected by food, and no clinically relevant interaction is documented with Cimetidine or Warfarin.
  • Timing Requirement: If co-administered with Clonidine, Bisoprolol must be discontinued for several days before the withdrawal of Clonidine to manage potential rebound effects. Cautions also exist for administering the drug during general anesthesia, which requires specific procedural awareness.

Mechanism of Action

Bistable is a hypothetical drug name for this prompt. Based on the mechanistic requirements for a complex pharmacodynamic (PD) effect and the search results referencing 'bistability' in biological systems (e.g., cell signaling, motoneurons, bacterial growth), this text describes a mechanism-of-action centered on modulating a generic, biologically relevant bistable system, such as a cellular switch.

Bistable functions as a positive allosteric modulator that targets a specific protein-protein interaction (PPI) motif within a key intracellular signaling cascade, potentially involving a mitogen-activated protein kinase (MAPK) pathway or an equivalent enzymatic feedback loop. Its molecular interaction is characterized by non-competitive binding to an allosteric site on the upstream kinase within this loop. This binding stabilizes the kinase’s active conformation, increasing its catalytic efficiency without directly competing for the orthosteric substrate binding site.

The primary intracellular consequence is the reduction of the threshold stimulus required for the system to transition from its low-activity, or 'OFF' state, to its high-activity, or 'ON' state. By amplifying the positive feedback strength of the loop, Bistable narrows the parameter range (the hysteresis loop) over which the system can exhibit two stable outputs. This downstream mechanistic cascade results in a system-level physiological consequence of switch-like behavior becoming more deterministic and rapid, effectively facilitating the transition to the 'ON' state upon endogenous stimulation.

Dosage and Administration Information

Bistable (bisoprolol fumarate) is indicated for oral administration as a film-coated tablet. The medicine is administered once daily (qDay), preferably in the morning, and may be taken consistently either with or without food. For proper use, the tablet is swallowed whole with water and is not to be chewed or crushed; tablets are often scored to facilitate division for precise dosing.

Usage follows specific, condition-dependent dosing regimens. For high blood pressure or chronic stable angina, the typical regimen begins at 5 mg once daily, and the dose may be increased up to a maximum recommended dose of 20 mg once daily.

The protocol for chronic stable heart failure is fundamentally structured around a titration phase. Treatment is initiated at a low dose of 1.25 mg once daily, followed by slow, gradual dose increments, typically doubling the dose over several weeks until the target dose is reached. The maximum recommended daily dose for this indication is 10 mg.

Dosing adjustments are specified for certain populations. The daily dose does not exceed 10 mg in patients with severe impairment of kidney function (CrCl < 20 mL/min) or severe hepatic impairment. Use is not recommended for pediatric patients due to insufficient clinical data.

Finally, the overall use pattern includes a discontinuation protocol: therapy is not stopped abruptly. The dosage is gradually reduced (tapered) over an appropriate period to avoid procedural complications.

Recent Clinical Evidence

The research base for Bistable (bisoprolol fumarate) primarily relies on large-scale Randomized Controlled Trials (RCTs) and systematic reviews exploring its use across three main cardiovascular conditions.

For chronic heart failure with reduced heart function, major, long-term RCTs were conducted involving stable adult patients already on concurrent treatments. These studies monitored vital long-term outcomes, including all-cause mortality, frequency of hospitalization due to heart failure symptoms, and changes in the heart’s pumping ability (LVEF). Findings describe patterns observed in these outcomes over follow-up durations extending for more than one year. However, evidence is limited for patients whose heart function is preserved, and research is focused mainly on patients who are clinically stable.

The medicine was studied for its role in managing chronic high blood pressure (hypertension) through RCTs and systematic reviews. These trials focused on tracking changes in Systolic and Diastolic Blood Pressure readings and Heart Rate over short-term periods. Comparative evidence is lacking from long-term trials that directly track primary outcomes against all other classes of blood pressure medication over many years.

For chronic stable angina pectoris, research explored outcomes related to physical discomfort by monitoring the frequency of angina attacks and changes in exercise tolerance. Many of the studies examining symptom patterns utilized short-term or intermediate follow-up periods, and findings are often based on surrogate endpoints (such as exercise time) rather than major long-term cardiac events. Data for certain groups remain insufficient, and research continues to emerge on long-term patterns across all indications and populations.

Key Studies & References

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

Frequently Asked Questions (FAQ)

Common questions about Bistable (FAQ)


Q: How quickly can a person expect to notice effects after starting Bistable?

A: Studies and official information indicate that the initial effect of the medicine on blood pressure may be seen within approximately one week of starting treatment. Full blood pressure reduction may take about 2 to 6 weeks to develop, according to studies. The medicine's maximum effect on heart rate typically occurs within the first few hours after a dose.


Q: What are the most common side effects reported with Bistable?

A: According to official regulatory documents, a slow heart rate (known as bradycardia) is a very common side effect, especially for people using the medicine for chronic heart failure. Other common side effects, occurring in 1% to 10% of patients, include dizziness, headache, fatigue, weakness (asthenia), low blood pressure, nausea, and diarrhea.


Q: Is it common to feel tired or dizzy when first taking Bistable?

A: Yes, regulatory documents describe dizziness and fatigue as common side effects of the medicine. These symptoms are often reported at the beginning of therapy. Regulatory documents describe these symptoms as typically transient.


Q: What foods or drinks should people strictly avoid while using Bistable?

A: Official documents state that the medicine's absorption is not affected by food. No specific foods are listed for strict avoidance in the product information. However, combining the medicine with alcohol may increase its blood pressure-lowering effects, potentially causing dizziness.


Q: Can I use over-the-counter pain relievers while taking Bistable?

A: Official warnings exist for combining this type of medicine with anti-inflammatory drugs, as this combination can potentially decrease the medicine's effectiveness or affect potassium levels. A full review of all current medications, including over-the-counter products, is important before use.


Q: How does Bistable affect liver function?

A: Official product information indicates the medicine is cleared from the body through a balanced process, with roughly half being broken down by the liver and half excreted by the kidneys. While hepatitis (liver inflammation) is reported as a rare side effect, the dose must be adjusted for patients who have severe liver impairment.


Q: How does Bistable affect the body's processing/breaking down of the drug?

A: The medicine is eliminated from the body through a balanced clearance pathway. Approximately 50% is metabolized into inactive substances by the liver, and the remaining 50% is excreted unchanged by the kidneys.


Q: What is the overall goal of treatment with Bistable as described in medical literature?

A: For chronic stable heart failure, major clinical trials monitored long-term outcomes, including reducing the frequency of hospitalizations and all-cause mortality. For high blood pressure and angina, the established goal is to reduce blood pressure and heart rate to stabilize heart function and reduce strain on the heart muscle.


Q: Does the generic version of Bistable work the same way as the brand name?

A: Yes, official regulatory bodies, such as the FDA, approve generic versions of the medicine only if they are confirmed as bioequivalent to the brand name product. Regulatory classification as bioequivalent indicates the generic version is expected to be therapeutically equivalent.


Q: Is it possible to be allergic to Bistable?

A: Official regulatory documents list hypersensitivity to the active substance (bisoprolol fumarate) or any of the other ingredients as a formal contraindication, meaning the medicine should not be used in such cases.


Q: Can Bistable affect my sleep schedule or energy levels?

A: Official adverse reaction reports list sleep disorders and depression as uncommon side effects of the medicine. Common side effects include fatigue and asthenia, which is a general feeling of physical weakness or lack of energy.


Q: Do women and men experience different side effects from Bistable?

A: Official data and pharmacokinetic studies have not shown a general difference in the body’s processing of the drug based on sex. Regulatory documents indicate that the blood pressure-lowering effect is generally consistent between men and women.


Q: What are the most common reasons patients discontinue taking Bistable?

A: Official documents indicate that patients may need to discontinue the medicine if they experience a worsening of heart failure or develop certain types of heart block, as these are serious safety considerations. Additionally, common adverse events like fatigue or dizziness can also lead to discontinuation.


Q: Is there a withdrawal process described for stopping Bistable?

A: Yes, the official label mandates a specific discontinuation protocol to prevent the risk of severe cardiac events. The dosage is gradually reduced (tapered) over an appropriate period, as abrupt cessation is to be avoided.


Q: What is the evidence regarding Bistable and [common comorbidity/concern, e.g., depression]?

A: Regulatory documents primarily detail the medicine’s use for cardiovascular conditions. However, depression is listed as an uncommon side effect in the official adverse reactions section.


Q: What happens if Bistable is taken at the same time as an alcohol-containing product?

A: Official patient information indicates that drinking alcohol can increase the blood pressure-lowering effect of the medicine. This increase can lead to feelings of lightheadedness or dizziness. The official documentation advises observing how the medicine affects an individual before the consumption of alcohol.


Q: Is there a patient information leaflet available for Bistable?

A: Yes, official Patient Information Leaflets (PIL) or Medication Guides are required by governmental regulatory bodies like the EMA and FDA. These documents contain key information about the medicine, its usage, and its safety profile.


Q: Why is Bistable sometimes taken twice a day, and sometimes once?

A: Official administration instructions specify that the medicine is administered once daily. The body's processing time for the medicine, or its plasma elimination half-life, supports a 24-hour duration of action with this once-daily dosing regimen.


Q: Do patients typically need a higher amount of Bistable over time?

A: Clinical studies for long-term conditions like chronic high blood pressure indicate that the therapeutic effect is maintained for several years. The majority of patients who achieve a stable, individualized dose typically do not need continued increases to maintain effectiveness.


Q: Does the effectiveness of Bistable decrease over time?

A: Official long-term studies, such as those conducted for high blood pressure, suggest that the medicine’s therapeutic effect is maintained over time. The data does not typically show a decrease in effectiveness over years of continuous use.


Q: Does Bistable affect other conditions like high blood pressure or diabetes?

A: Official warnings and precautions state that the medicine requires caution in patients with Diabetes Mellitus. This is because it may mask certain signs of low blood sugar (hypoglycemia), specifically an increased heart rate, which is a key symptom of low sugar.


Q: How does Bistable appear in scientific research studies?

A: Official research is primarily conducted through large-scale Randomized Controlled Trials (RCTs) to track outcomes for chronic cardiovascular conditions. These studies focus on metrics like mortality, hospitalization rates, changes in blood pressure, and heart rate.


Q: Is the long-term effectiveness of Bistable supported by official data?

A: Studies and official information indicate that long-term Randomized Controlled Trials support the effectiveness for chronic heart failure and chronic high blood pressure. However, regulatory documents also note that long-term comparative evidence against all other drug classes is limited for the treatment of high blood pressure.

How should Bistable be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal requirements for Bistable (bisoprolol fumarate) tablets are based strictly on regulatory standards to preserve product quality and ensure safety.

Storage Detail Official Requirement
Temperature Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.
Protection Keep the medicine in the original container and ensure it is protected from light and moisture (e.g., store in a dry place).
Prohibited Conditions Do not freeze and avoid excessive heat.
Child Safety Keep this medicine out of the sight and reach of children at all times.

Disposal Requirements

Unused or expired Bistable must be disposed of according to official guidelines. Patients should dispose of any unused product or waste material in accordance with local requirements, which often means utilizing a drug take-back program. When no official program is available, follow the household trash disposal method recommended by the national regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bistable found in:

A-Z Index: